Search Results - "Mary J. Clark"

Binding pathway determines norepinephrine selectivity for the human β1AR over β2AR by Xu, Xinyu, Kaindl, Jonas, Clark, Mary J., Hübner, Harald, Hirata, Kunio, Sunahara, Roger K., Gmeiner, Peter, Kobilka, Brian K., Liu, Xiangyu

“…Beta adrenergic receptors (βARs) mediate physiologic responses to the catecholamines epinephrine and norepinephrine released by the sympathetic nervous system…”
Get full text

Constrained catecholamines gain β2AR selectivity through allosteric effects on pocket dynamics by Xu, Xinyu, Shonberg, Jeremy, Kaindl, Jonas, Clark, Mary J., Stößel, Anne, Maul, Luis, Mayer, Daniel, Hübner, Harald, Hirata, Kunio, Venkatakrishnan, A. J., Dror, Ron O., Kobilka, Brian K., Sunahara, Roger K., Liu, Xiangyu, Gmeiner, Peter

“…G protein-coupled receptors (GPCRs) within the same subfamily often share high homology in their orthosteric pocket and therefore pose challenges to drug…”
Get full text

Structure-guided development of selective M3 muscarinic acetylcholine receptor antagonists by Liu, Hongtao, Hofmann, Josefa, Fish, Inbar, Schaake, Benjamin, Eitel, Katrin, Bartuschat, Amelie, Kaindl, Jonas, Rampp, Hannelore, Banerjee, Ashutosh, Hübner, Harald, Clark, Mary J., Vincent, Sandra G., Fisher, John T., Heinrich, Markus R., Hirata, Kunio, Liu, Xiangyu, Sunahara, Roger K., Shoichet, Brian K., Kobilka, Brian K., Gmeiner, Peter

“…Drugs that treat chronic obstructive pulmonary disease by antagonizing the M3 muscarinic acetylcholine receptor (M3R) have had a significant effect on health,…”
Get full text

An allosteric modulator binds to a conformational hub in the β2 adrenergic receptor by Liu, Xiangyu, Kaindl, Jonas, Korczynska, Magdalena, Stößel, Anne, Dengler, Daniela, Stanek, Markus, Hübner, Harald, Clark, Mary J., Mahoney, Jake, Matt, Rachel Ann, Xu, Xinyu, Hirata, Kunio, Shoichet, Brian K., Sunahara, Roger K., Kobilka, Brian K., Gmeiner, Peter

“…Most drugs acting on G-protein-coupled receptors target the orthosteric binding pocket where the native hormone or neurotransmitter binds. There is much…”
Get full text

Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor by Burford, Neil T., Clark, Mary J., Wehrman, Tom S., Gerritz, Samuel W., Banks, Martyn, O'Connell, Jonathan, Traynor, John R., Alt, Andrew

“…μ-Opioid receptors are among the most studied G protein-coupled receptors because of the therapeutic value of agonists, such as morphine, that are used to…”
Get full text

Author Correction: Constrained catecholamines gain β2AR selectivity through allosteric effects on pocket dynamics by Xu, Xinyu, Shonberg, Jeremy, Kaindl, Jonas, Clark, Mary J., Stößel, Anne, Maul, Luis, Mayer, Daniel, Hübner, Harald, Hirata, Kunio, Venkatakrishnan, A. J., Dror, Ron O., Kobilka, Brian K., Sunahara, Roger K., Liu, Xiangyu, Gmeiner, Peter

Get full text

Structure-Based Design and Discovery of New M2 Receptor Agonists by Fish, Inbar, Stößel, Anne, Eitel, Katrin, Valant, Celine, Albold, Sabine, Huebner, Harald, Möller, Dorothee, Clark, Mary J, Sunahara, Roger K, Christopoulos, Arthur, Shoichet, Brian K, Gmeiner, Peter

“…Muscarinic receptor agonists are characterized by apparently strict restraints on their tertiary or quaternary amine and their distance to an ester or related…”
Get full text

Nucleus accumbens shell excitability is decreased by methamphetamine self-administration and increased by 5-HT2C receptor inverse agonism and agonism by Graves, Steven M., Clark, Mary J., Traynor, John R., Hu, Xiu-Ti, Napier, T. Celeste

“…Methamphetamine profoundly increases brain monoamines and is a widely abused psychostimulant. The effects of methamphetamine self-administration on neuron…”
Get full text

Structure of a D2 dopamine receptor–G-protein complex in a lipid membrane by Yin, Jie, Chen, Kuang-Yui M., Clark, Mary J., Hijazi, Mahdi, Kumari, Punita, Bai, Xiao-chen, Sunahara, Roger K., Barth, Patrick, Rosenbaum, Daniel M.

“…The D2 dopamine receptor (DRD2) is a therapeutic target for Parkinson’s disease 1 and antipsychotic drugs 2 . DRD2 is activated by the endogenous…”
Get full text

Structure and selectivity engineering of the M 1 muscarinic receptor toxin complex by Maeda, Shoji, Xu, Jun, N Kadji, Francois Marie, Clark, Mary J, Zhao, Jiawei, Tsutsumi, Naotaka, Aoki, Junken, Sunahara, Roger K, Inoue, Asuka, Garcia, K Christopher, Kobilka, Brian K

“…Muscarinic toxins (MTs) are natural toxins produced by mamba snakes that primarily bind to muscarinic acetylcholine receptors (MAChRs) and modulate their…”
Get full text

Leveraging nonstructural data to predict structures and affinities of protein–ligand complexes by Paggi, Joseph M., Belk, Julia A., Hollingsworth, Scott A., Villanueva, Nicolas, Powers, Alexander S., Clark, Mary J., Chemparathy, Augustine G., Tynan, Jonathan E., Lau, Thomas K., Sunahara, Roger K., Dror, Ron O.

“…Over the past five decades, tremendous effort has been devoted to computational methods for predicting properties of ligands—i.e., molecules that bind…”
Get full text

Structure-based discovery of selective positive allosteric modulators of antagonists for the M₂ muscarinic acetylcholine receptor by Korczynska, Magdalena, Clark, Mary J., Valant, Celine, Xu, Jun, Von Moo, Ee, Albold, Sabine, Weiss, Dahlia R., Torosyan, Hayarpi, Huang, Weijiao, Kruse, Andrew C., Lyda, Brent R., May, Lauren T., Baltos, Jo-Anne, Sexton, Patrick M., Kobilka, Brian K., Christopoulos, Arthur, Shoichet, Brian K., Sunahara, Roger K.

“…Subtype-selective antagonists for muscarinic acetylcholine receptors (mAChRs) have long been elusive, owing to the highly conserved orthosteric binding site…”
Get full text

Developmental Monitoring and Referral for Low-Income Children Served by WIC: Program Development and Implementation Outcomes by Farmer, Janet E., Falk, Lee Walker, Clark, Mary J., Mayfield, Wayne A., Green, Katie K.

“…Objective To develop, implement, and assess implementation outcomes for a developmental monitoring and referral program for children in the Special…”
Get full text

Structure and selectivity engineering of the M1 muscarinic receptor toxin complex by Maeda, Shoji, Xu, Jun, N Kadji, Francois Marie, Clark, Mary J, Zhao, Jiawei, Tsutsumi, Naotaka, Aoki, Junken, Sunahara, Roger K, Inoue, Asuka, Garcia, K Christopher, Kobilka, Brian K

“…Engineering a toxinDeveloping drugs that target a specific subtype in a G protein–coupled receptor (GPCR) family is a major challenge. Maeda et al. examined…”
Get full text

The Relationship Between the Medical Home and Unmet Needs for Children with Autism Spectrum Disorders by Farmer, Janet E., Clark, Mary J., Mayfield, Wayne A., Cheak-Zamora, Nancy, Marvin, Alison R., Law, J. Kiely, Law, Paul A.

“…The purpose of this study was to examine the relationship between having access to a medical home and unmet needs for specialty care services for children with…”
Get full text

C7β-Methyl Analogues of the Orvinols: The Discovery of Kappa Opioid Antagonists with Nociceptin/Orphanin FQ Peptide (NOP) Receptor Partial Agonism and Low, or Zero, Efficacy at Mu Opioid Receptors by Cueva, Juan Pablo, Roche, Christopher, Ostovar, Mehrnoosh, Kumar, Vinod, Clark, Mary J, Hillhouse, Todd M, Lewis, John W, Traynor, John R, Husbands, Stephen M

“…Buprenorphine is a successful analgesic and treatment for opioid abuse, with both activities relying on its partial agonist activity at mu opioid receptors…”
Get full text

Consultative Care Coordination Through the Medical Home for CSHCN: A Randomized Controlled Trial by Farmer, Janet E., Clark, Mary J., Drewel, Elena Harlan, Swenson, Theresa M., Ge, Bin

“…The purpose of this study was to examine the impact of a care coordination intervention aimed at improving the medical home for children with special health…”
Get full text

Act Healthy: promoting health behaviors and self-efficacy in the workplace by Schopp, Laura H., Bike, Denise H., Clark, Mary J., Minor, Marian A.

“…Chronic health conditions and multiple health risk factors afflict Americans and burden employers, but effective, affordable, workplace-based health promotion…”
Get full text

Opioid Peptidomimetics: Leads for the Design of Bioavailable Mixed Efficacy μ Opioid Receptor (MOR) Agonist/δ Opioid Receptor (DOR) Antagonist Ligands by Mosberg, Henry I, Yeomans, Larisa, Harland, Aubrie A, Bender, Aaron M, Sobczyk-Kojiro, Katarzyna, Anand, Jessica P, Clark, Mary J, Jutkiewicz, Emily M, Traynor, John R

“…We have previously described opioid peptidomimetic, 1, employing a tetrahydroquinoline scaffold and modeled on a series of cyclic tetrapeptide opioid agonists…”
Get full text

Orvinols with Mixed Kappa/Mu Opioid Receptor Agonist Activity by Greedy, Benjamin M, Bradbury, Faye, Thomas, Mark P, Grivas, Konstantinos, Cami-Kobeci, Gerta, Archambeau, Ashley, Bosse, Kelly, Clark, Mary J, Aceto, Mario, Lewis, John W, Traynor, John R, Husbands, Stephen M

“…Dual-acting kappa opioid receptor (KOR) agonist and mu opioid receptor (MOR) partial agonist ligands have been put forward as potential treatment agents for…”
Get full text